sb 203580 has been researched along with gentiopicroside in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (gentiopicroside) | Trials (gentiopicroside) | Recent Studies (post-2010) (gentiopicroside) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 174 | 0 | 120 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jiang, Y; Mu, F; Wu, H; You, Q; Zhang, N | 1 |
1 other study(ies) available for sb 203580 and gentiopicroside
Article | Year |
---|---|
Gentiopicrin exerts anti-rheumatic effect in human fibroblast-like synoviocytes via inhibition of p38MAPK/NF-κB pathway.
Topics: Arthritis, Rheumatoid; Cell Survival; Cells, Cultured; Fibroblasts; Humans; Imidazoles; Interleukin-1beta; Interleukin-6; Iridoid Glucosides; NF-kappa B; Nitriles; p38 Mitogen-Activated Protein Kinases; Plant Extracts; Pyridines; RNA, Messenger; Signal Transduction; Sulfones; Synoviocytes; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2019 |